Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The drug Pfizer is licensing comes from Shenyang, China-based 3SBio. Under deal terms announced earlier this week, Pfizer is paying $1.25 billion up front for global rights to the biologic ...

The deal, which excludes China but provides Pfizer with an option for commercialization rights within the country, involves an upfront payment of $1.25 billion to 3SBio.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Novo Nordisk NVO announced the surprise resignation of its chief executive officer (CEO), Lars Fruergaard Jørgensen. Sanofi ...

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, ...

The license deal grants Pfizer (PFE) an exclusive global license ... as well as an option for commercialization rights in China. 3SBio will receive an upfront payment of $1.25B and is eligible ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Pfizer has struck a massive $1.25 billion deal with China’s 3SBio to license a promising cancer drug, beefing up its oncology ...